share_log

T2 Biosystems | SC 13D: Statement of acquisition of beneficial ownership by individuals-Nathan D. Hukill(46.68%),CR Group L.P.(46.68%), etc.

SEC announcement ·  Apr 20 04:36
Summary by Futu AI
On April 12, 2024, a significant change in ownership was reported for T2 Biosystems, Inc., a company specializing in medical diagnostic technology. A group led by Nathan D. Hukill, including CR Group L.P. and various CRG Partners funds, filed a Schedule 13D with the SEC, indicating they had collectively acquired a 46.68% beneficial ownership in T2 Biosystems. This acquisition was the result of a debt cancellation agreement in exchange for common stock, which was previously reported in a Schedule 13G filing. The group's beneficial ownership crossed the 20% threshold, triggering the Schedule 13D filing requirement. The shares were acquired for investment purposes with the intention of increasing the value of their investment in T2 Biosystems. The group may consider acquiring additional shares or disposing of their holdings in the future. The principal business of the group is healthcare-focused investments, and they have not been involved in any legal proceedings related to securities laws in the past five years.
On April 12, 2024, a significant change in ownership was reported for T2 Biosystems, Inc., a company specializing in medical diagnostic technology. A group led by Nathan D. Hukill, including CR Group L.P. and various CRG Partners funds, filed a Schedule 13D with the SEC, indicating they had collectively acquired a 46.68% beneficial ownership in T2 Biosystems. This acquisition was the result of a debt cancellation agreement in exchange for common stock, which was previously reported in a Schedule 13G filing. The group's beneficial ownership crossed the 20% threshold, triggering the Schedule 13D filing requirement. The shares were acquired for investment purposes with the intention of increasing the value of their investment in T2 Biosystems. The group may consider acquiring additional shares or disposing of their holdings in the future. The principal business of the group is healthcare-focused investments, and they have not been involved in any legal proceedings related to securities laws in the past five years.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.